Biovail Corporation Earnings Conference Call (Q1 2008)  Today's Calls

Visit the TF Network Sites· Corporate IR Center · Institutional Investor Center · Individual Investor Center Download Plug-In Real Player 8 Basic Windows Media Player Other Conference Calls Other May 8 Calls Today's Calls

Call Details Biovail Corporation Earnings Conference Call (Q1 2008) Thu, May 8, 2008, 8:30 am Eastern Listen to the archived event audio About Biovail Corporation (NYSE:BVF) Biovail Corporation, a pharmaceutical company, engages in the formulation, clinical testing, registration, manufacture, and commercialization of pharmaceutical products utilizing various drug-delivery technologies in the United States and Canada. The company principally focuses on central nervous system disorders, pain management, and cardiovascular diseases. It offers Wellbutrin XL for the treatment of depression in adults; Ultram ER for the management of chronic pain in adults; Zovirax Ointment for the management of initial genital herpes; Zovirax Cream for the treatment of herpes labialis; and Cardizem LA that provides blood pressure control. The company also provides Tiazac/Tiazac XC for the treatment of hypertension and angina; Wellbutrin SR/Zyban for the treatment of depression; Monocor for the treatment of mild to moderate hypertension and congestive heart failure; Retavase, a tissue plasminogen activator used in thrombolytic therapy; Glumetza to control hyperglycemia in adult patients with non-insulin dependent and mature onset diabetes; and Ralivia for the management of pain in patients. Its legacy products comprise Cardizem CD medications in the calcium channel blocker category of cardiovascular drugs; Ativan for the management of anxiety disorders, short-term relief of anxiety, or anxiety associated with symptoms of depression; Tiazac used in the treatment of hypertension and angina; Vasotec/Vaseretic for the treatment of hypertension, symptomatic congestive heart failure, and asymptomatic left ventricular dysfunction; and Isordil to treat prophylaxis of ischemic heart pain associated with coronary insufficiency. The company’s generic products consist of bioequivalent formulations of Cardizem CD, Adalat CC, Procardia XL, Tiazac, Voltaren XR, and Trental. In addition, Biovail Corporation offers research, development, and clinical contract research services to third parties. The company was founded in 1983 and is headquartered in Mississauga, Canada. More Info: Quote | Chart | Profile | Reports | Research | Msgs | Financials | Analyst Ratings